Sample: What tobacco product was most commonly used among US adults in 2018? E-cigarettes? Traditional cigarettes? Neither? The answer may surprise.
FDA Approves First Oral GLP-1 Receptor Agonist for Chronic Weight Management
December 23rd 2025The FDA approved once-daily oral semaglutide 25 mg for chronic weight management and long-term weight maintenance in adults with obesity or overweight, based on data from the OASIS clinical trial program.
Phase 3 Data Support Oral Orforglipron for Weight Maintenance After GLP-1–Based Weight Loss
December 19th 2025Topline Phase 3 ATTAIN-MAINTAIN data show oral orforglipron met primary and key secondary endpoints for weight maintenance after prior GLP-1–based injectable therapy in adults with obesity.